Testa Advances in Drug Research

1. Auflage 2013
ISBN: 978-1-4832-8798-0
Verlag: Elsevier Science & Techn.
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, Band Volume 18, 549 Seiten, Web PDF

Reihe: Advances in Drug Research

Each volume in this distinguished series presents authoritative reviews, both generally, on topics of broad interest in drug research, and specifically, on novel and established therapeutic classes. Acknowledged experts contribute in areas such as drug design, clinical and molecular pharmacology, drug metabolism, and mechanisms of action. Reviewers have consistently praised Advances in Drug Research for its comprehensive and lucid summaries of up-to-date knowledge.

Autoren/Hrsg.

Testa, Bernard

Inhaltsverzeichnis

1;Front Cover;1
2;Advances in Drug Research;4
3;Copyright Page;5
4;Table of Contents;6
5;CONTRIBUTORS;10
6;PREFACE: AT THE FUNFAIR?;12
6.1;References;14
7;Chapter 1. Molecular Mechanisms of Specificity in DNA–Antitumour Drug Interactions;16
7.1;1 Introduction: The Main Modes of Binding of Antitumour Drugs to DNA;17
7.2;2 Factors Governing the Specificity of Interaction of Non-intercalating Groove-binding Antitumour Drugs with DNA;24
7.3;3 Factors Governing the Specificity of Interaction of Intercalating Antitumour Drugs with DNA;68
7.4;4 Factors Involved in the Sequence-selective Interaction of Covalently Bound Antitumour Drugs with DNA;101
7.5;5 Concluding Remarks;118
7.6;Acknowledgement;121
7.7;References;121
8;Chapter 2.
The Structure and Receptor Binding of Steroid Hormones;130
8.1;1 Introduction;131
8.2;2 Steroid Structure and Receptor Binding;132
8.3;3 Steroid Hormone Antagonists;140
8.4;4 Steroid Receptor Structures;146
8.5;5 Summary;148
8.6;Acknowledgements;150
8.7;References;150
9;Chapter 3. Aldose Reductase Inhibitors: Structure–Activity Relationships and Therapeutic Potential;154
9.1;1 Introduction;154
9.2;2 Structure-Activity Relationships of Aldose Reductase Inhibitors;159
9.3;3 Therapeutic Potential of Aldose Reductase Inhibitors;175
9.4;4 Conclusion;184
9.5;References;184
10;Chapter 4.
Opioid Receptors and their Ligands: Recent Developments;192
10.1;1 Introduction;193
10.2;2 Novel Opiates;195
10.3;3 Opioid Peptides;225
10.4;4 Affinity Labelling;244
10.5;5 Receptor Subtype Investigations;252
10.6;6 Opioid Receptors: Facts and Scenarios;272
10.7;7 Concluding Remarks;286
10.8;References;287
11;Chapter 5.
Purine Receptors and their Pharmacological Roles;306
11.1;1 Introduction;307
11.2;2 Purine Receptors;309
11.3;3 Physiological Roles and Pharmacological Activity;357
11.4;4 Concluding Remarks;422
11.5;References;424
12;Chapter 6.
Muscarinic Cholinergic Receptors and their Interactions with Drugs;446
12.1;1 Introduction;447
12.2;2 Receptor Characterization by Means of Binding Studies;451
12.3;3 Binding of Radiolabelled Ligands to Muscarinic Receptors;456
12.4;4 Allosteric and Cooperative Interactions of Muscarinic Receptors;460
12.5;5 Binding of Agonists;466
12.6;6 Localization of Muscarinic Receptors;472
12.7;7 Subtypes of Muscarinic Receptors;477
12.8;8 Regulation of Muscarinic Receptors and their Interaction with Other Membrane Proteins;482
12.9;9 The Membrane Matrix and Lateral Mobility;491
12.10;10 Purification of the Muscarinic Receptor;493
12.11;11 Molecular Properties of Muscarinic Receptors;499
12.12;12 From Ontogeny to Ageing;508
12.13;13 Concluding Remarks;511
12.14;Acknowledgements;513
12.15;References;513
13;SUBJECT INDEX;526
14;CUMULATIVE INDEX OF AUTHORS;560
15;CUMULATIVE INDEX OF TITLES;562